debt_leverage_profile
Pre-revenue clinical-stage biotech; minimal debt, equity-funded via private placements; 20% rate rise immaterial to current structure
Inferred
Agent_Inference
interest_rate_sensitivity
Low sensitivity; no significant floating-rate debt; higher rates increase cost of future equity dilution as risk-free hurdle rises
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Psilocybin API sourcing (Jamaica/Netherlands regulatory hubs) and GMP-certified API manufacturers concentrated in limited jurisdictions
Inferred
Agent_Inference
international_expansion_readiness
Primarily CAD/USD exposure; limited international revenue markets; sovereign currency devaluation risk is minimal at current pre-commercial stage
Inferred
Agent_Inference
geographic_footprint
Operations in Canada and Jamaica; revenues negligible; CAD depreciation vs USD is primary currency risk for cross-border clinical costs
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Single-source GMP psilocybin supplier likely represents non-substitutable input; switching risk high given regulatory re-validation requirements
Inferred
Agent_Inference
business_model_type_primary
Clinical-stage pharmaceutical/biotech; cloud infrastructure not central to operations; 30-day AWS termination would minimally disrupt core drug development
Inferred
Agent_Inference
business_model_type_secondary
Data management and trial systems could face disruption; transferable within 60–90 days to alternative cloud; not existential
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; uses standard clinical trial software and CRO platforms; no proprietary API lock-in identified
Inferred
Agent_Inference
howey_test_risk_index
Revenue model is drug licensing/royalties, not token-based; Howey Test largely inapplicable; no securities-as-utility risk flagged
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Clinical trial patient data subject to GDPR (if EU sites) and Canadian PIPEDA; CCPA exposure limited; compliance infrastructure standard for biotech
Inferred
Agent_Inference
antitrust_exposure_flag
Minimal antitrust exposure; niche psychedelic-assisted therapy market; no dominant market share or exclusionary conduct identified
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Currently 0% recurring revenue; pre-commercial stage; future model expected to be milestone-based licensing plus eventual royalty streams
Inferred
Agent_Inference
monetization_vector
Primary monetization via pharmaceutical licensing deals, partnership milestones, and eventual royalties on approved psychedelic therapeutics
Inferred
Agent_Inference
pricing_architecture
No commercial pricing yet; future pricing will benchmark against ketamine therapy (~$700–$1,200/session) and SPRAVATO (~$800/dose)
Inferred
Agent_Inference
pricing_power_rating
Moderate-to-high potential pricing power if FDA/Health Canada approval achieved; psychedelic-assisted therapy faces reimbursement headwinds
Inferred
Agent_Inference
target_gross_margin_bracket
Pharmaceutical royalty/licensing model targets 70–85% gross margins at commercial scale; current gross margin is negative (R&D spend only)
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider leakage problem; proprietary formulations and regulatory exclusivity provide IP moat; not a platform with open-access risk
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is sublinear to headcount; licensing model scales without proportional headcount; CRO-outsourced trials limit fixed labor cost
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of scaling via licensing near-zero post-approval; R&D cost per new indication is primary growth cost driver
Inferred
Agent_Inference
franchise_compliance_risk
Not a franchise business model; not applicable
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC remains low (B2B pharma licensing); customer is large pharma/health system; sales cycle long but CAC/LTV ratio favorable
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; value derived from clinical data exclusivity and IP, not user network density
Inferred
Agent_Inference
asset_efficiency_ratio
AI displacement risk low for core drug development; AI may accelerate trial design and patient matching but cannot replace regulatory approval process
Inferred
Agent_Inference
recession_resistance_tier
Moderate recession resistance; mental health demand is countercyclical but reimbursement and elective treatment spending contract in downturns
Inferred
Agent_Inference
customer_segment_primary
Pharmaceutical/biotech licensing partners and healthcare institutions seeking psychedelic-assisted therapy programs
Inferred
Agent_Inference
customer_segment_secondary
Specialty mental health clinics and research hospitals participating in psilocybin clinical trials
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital allocated entirely to future-state R&D and clinical infrastructure; no legacy operations to reallocate from; fully forward-looking spend
Inferred
Agent_Inference
sec_cik
0001985062
High
SEC-EDGAR
ticker
PBM
High
SEC-EDGAR